Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques
- 2 September 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 22 (9) , 1193-1208
Abstract
: Ocular gene therapy represents fertile ground for rapid innovation, with ever-expanding therapeutic strategies, molecular targets, and indications.: Potential indications for ocular gene therapy ...Keywords
This publication has 88 references indexed in Scilit:
- A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010BMJ Open, 2014
- Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approachGene Therapy, 2013
- Adeno-Associated Virus Antibody Profiles in Newborns, Children, and AdolescentsClinical and Vaccine Immunology, 2011
- C-reactive protein and complement factor H in aged human eyes and eyes with age-related macular degenerationBritish Journal of Ophthalmology, 2011
- Novel Properties of Tyrosine-mutant AAV2 Vectors in the Mouse RetinaMolecular Therapy, 2011
- Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78Proceedings of the National Academy of Sciences, 2010
- Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosaNature Neuroscience, 2008
- Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroidProceedings of the National Academy of Sciences, 2006
- Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectorsThe Journal of Gene Medicine, 2005
- Systematic Determination of the Packaging Limit of Lentiviral VectorsHuman Gene Therapy, 2001